Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medic...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898026/ |